Q-omics provides the consensus-scored DLEU2 profile across patient tissues and cancer cell-line models. DLEU2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, DLEU2 is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, DLEU2 RNA expression shows 19,549 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, HNSC, and UVM as cancer lineages where DLEU2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DLEU2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DLEU2 survival associations across molecular data types. DLEU2 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DLEU2 RNA expression–survival associations across cancer types. High DLEU2 expression shows unfavorable associations in KIRP, UVM, KIRC, ACC, KICH and LIHC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for DLEU2 RNA expression.
This table summarizes DLEU2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DLEU2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DLEU2 shows higher tumor expression in HNSC, KIRC, BLCA, STAD, COAD and THCA. The HNSC box plot shows higher DLEU2 RNA expression in tumor versus normal tissue (log2 FC = +1.220, t-test p < 0.001).
This table shows molecular features associated with DLEU2 in patient tissues and cancer cell lines. In patient samples, DLEU2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, DLEU2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
